Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management

HONG KONG, Sept. 29, 2023 /PRNewswire/ -- Pfizer announced the availability of Rimegepant in Hong Kong, the first market in Asia, a calcitonin gene-related

Related Keywords

Thailand ,Macau ,United States ,United Kingdom ,Hong Kong ,Krishnamoorthy Sundaresan ,Brain Research United Kingdom ,Youtube ,Exchange Commission ,Pfizer ,International Headache Society ,Pfizer Corporation Hong Kong ,European Union ,General Manager ,Pfizer Hong Kong ,Breakthroughs That Change Patient ,Annual Report ,Looking Information ,Factors That May Affect Future ,Face Pain ,Research United ,Thailand Business ,